EGFR and non-small cell lung carcinoma: This dual base editing approach achieved editing frequencies of 6.1% in TP53 and 27.1% in EGFR in a xenograft mouse model of NSCLC, enhancing sensitivity to gefitinib and leading to successful tumor regression.